NRXPW NRX Pharmaceuticals, Inc. - Warrant
$0.01
가격 · 5월 20, 2026
기준 재무 정보 3월 23, 2026
NRXPW 주식 스냅샷 가격, 시가총액, P/E, EPS, ROE, 부채/자본, 52주 범위
가격
$0.01
시가총액
$2M
P/E (TTM)
-0.0
EPS (TTM)
—
매출 (TTM)
$1M
배당 수익률
—
ROE
111.0%
부채/자본
—
52주 범위
$0 – $0
NRXPW 주가 차트 기술 지표가 포함된 일일 OHLCV — 팬, 확대/축소 및 보기 사용자 정의
Configure
10년 성과 매출, 순이익, 마진 및 EPS 추세
매출 및 순이익
$1M
2024-12-31
→
2025-12-31
EPS
—
2020-12-31
→
2022-12-31
잉여현금흐름
—
마진
-2336.5%
가치 평가 P/E, P/S, P/B, EV/EBITDA 비율 — 주식이 비싼가요, 싼가요?
지표
5년 추세
NRXPW
동종업계 중앙값
P/E (TTM)
-0.0
—
P/S (TTM)
2.0
—
P/B
-0.2
—
수익성 총, 영업 및 순이익률; ROE, ROA, ROIC
지표
5년 추세
NRXPW
동종업계 중앙값
Operating Margin (영업이익률)
-1324.4%
—
Net Profit Margin (순이익률)
-2336.5%
—
ROA
-344.7%
—
ROE
111.0%
—
재무 건전성 부채, 유동성, 지급능력 — 대차대조표 건전성
지표
5년 추세
NRXPW
동종업계 중앙값
Current Ratio (유동비율)
0.3
—
Quick Ratio (당좌 비율)
0.3
—
성장 매출, EPS 및 순이익 성장률: YoY, 3년 CAGR, 5년 CAGR
지표
5년 추세
NRXPW
동종업계 중앙값
자본 효율성 자산 회전율, 재고 회전율, 매출채권 회전율
지표
5년 추세
NRXPW
동종업계 중앙값
전체 기본 지표 연도별 모든 지표 — 손익계산서, 대차대조표, 현금흐름
손익계산서 13
| 지표 | 추세 | 2025 | 2024 |
|---|---|---|---|
| Revenue | $1M | $0 | |
| Cost of Revenue | $505.0K | $0 | |
| R&D Expense | $4M | $6M | |
| SG&A Expense | $13M | $14M | |
| Operating Expenses | $17M | $19M | |
| Operating Income | $-16M | $-19M | |
| Interest Income | $12.0K | $44.0K | |
| Other Non-op | $-12M | $-7M | |
| Income Tax | $0 | $0 | |
| Net Income | $-29M | $-25M | |
| EPS (Basic) | $-1.34 | $-2.36 | |
| Shares (Basic) | 21,401,683 | 10,644,461 | |
| EBITDA | $-16M | · |
대차대조표 21
| 지표 | 추세 | 2025 | 2024 |
|---|---|---|---|
| Cash & Equivalents | $8M | $1M | |
| Receivables | $161.0K | $0 | |
| Prepaid Expense | $934.0K | $2M | |
| Current Assets | $9M | $3M | |
| PP&E (Net) | $63.0K | $10.0K | |
| PP&E (Gross) | $93.0K | $29.0K | |
| Accum. Depreciation | $30.0K | $19.0K | |
| Goodwill | $2M | $0 | |
| Intangibles | $925.0K | $0 | |
| Other Non-current Assets | $253.0K | $339.0K | |
| Total Assets | $13M | $4M | |
| Accounts Payable | $4M | $4M | |
| Current Liabilities | $29M | $22M | |
| Total Liabilities | $29M | $27M | |
| Common Stock | $32.0K | $15.0K | |
| Paid-in Capital | $291M | $255M | |
| Retained Earnings | $-307M | $-278M | |
| AOCI | · | $0 | |
| Stockholders' Equity | $-16M | $-23M | |
| Liabilities + Equity | $13M | $4M | |
| Shares Outstanding | 31,734,333 | 14,591,505 |
현금 흐름 10
| 지표 | 추세 | 2025 | 2024 |
|---|---|---|---|
| D&A | $70.0K | $5.0K | |
| Stock-based Comp | $228.0K | $486.0K | |
| Operating Cash Flow | $-14M | $-11M | |
| CapEx | · | $0 | |
| Investing Cash Flow | $-3M | $0 | |
| Stock Issued | $6M | $0 | |
| Net Stock Activity | $6M | · | |
| Financing Cash Flow | $23M | $7M | |
| Net Change in Cash | $6M | $-3M | |
| Taxes Paid | $0 | $0 |
수익성 5
| 지표 | 추세 | 2025 | 2024 |
|---|---|---|---|
| Operating Margin | -1324.4% | · | |
| Net Margin | -2336.5% | · | |
| EBITDA Margin | -1324.4% | · | |
| ROA | -344.7% | · | |
| ROE | 111.0% | · |
유동성 및 지급능력 2
| 지표 | 추세 | 2025 | 2024 |
|---|---|---|---|
| Current Ratio | 0.3 | · | |
| Quick Ratio | 0.3 | · |
효율성 2
| 지표 | 추세 | 2025 | 2024 |
|---|---|---|---|
| Asset Turnover | 0.1 | · | |
| Receivables Turnover | 15.2 | · |
가치 평가 (TTM) 8
| 지표 | 추세 | 2025 | 2024 |
|---|---|---|---|
| Revenue TTM | $1M | $0 | |
| Net Income TTM | $-29M | $-25M | |
| Market Cap | $2M | · | |
| P/E | -0.0 | · | |
| P/S | 2.0 | · | |
| P/B | -0.2 | · | |
| P / Cash Flow | -0.2 | · | |
| Earnings Yield | -3372.4% | · |
손익계산서 13
| 지표 | 추세 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|
| Revenue | $983.0K | $242.0K | $0 | $0 | $0 | $0 | |
| Cost of Revenue | $408.0K | $97.0K | · | · | $0 | $0 | |
| R&D Expense | $558.0K | $1M | $987.0K | · | $1M | $611.0K | |
| SG&A Expense | $5M | $3M | $3M | · | $3M | $2M | |
| Operating Expenses | $6M | $4M | $4M | · | $2M | $3M | |
| Operating Income | $-5M | $-4M | $-4M | · | $-2M | $-3M | |
| Interest Income | $4.0K | $2.0K | $2.0K | · | $4.0K | $6.0K | |
| Other Non-op | $5M | $-2M | $-14M | · | $-7M | $1M | |
| Income Tax | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $361.0K | $-6M | $-18M | $-6M | $-9M | $-2M | |
| EPS (Basic) | $0.20 | $-0.27 | $-0.98 | · | $-0.72 | $-0.15 | |
| Shares (Basic) | 2,519,715 | 22,231,178 | 17,934,196 | · | -19,698,982 | 10,973,697 | |
| EBITDA | · | $-4M | $-4M | · | · | $-3M |
대차대조표 21
| 지표 | 추세 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $8M | $7M | $3M | $6M | $1M | $2M | |
| Receivables | $161.0K | $239.0K | · | · | $0 | · | |
| Prepaid Expense | $934.0K | $1M | $2M | $2M | $2M | $2M | |
| Current Assets | $9M | $12M | $5M | $7M | $3M | $4M | |
| PP&E (Net) | $63.0K | $69.0K | · | · | $10.0K | · | |
| PP&E (Gross) | $93.0K | $93.0K | · | · | $29.0K | · | |
| Accum. Depreciation | $30.0K | $24.0K | · | · | $19.0K | · | |
| Goodwill | $2M | $610.0K | · | · | $0 | · | |
| Intangibles | $925.0K | $2M | · | · | $0 | · | |
| Other Non-current Assets | $253.0K | $243.0K | $248.0K | $334.0K | $339.0K | $356.0K | |
| Total Assets | $13M | $15M | $5M | $8M | $4M | $4M | |
| Accounts Payable | $4M | $4M | $4M | $4M | $4M | $5M | |
| Current Liabilities | $29M | $41M | $40M | $33M | $22M | $20M | |
| Total Liabilities | $29M | $41M | $40M | $33M | $27M | $23M | |
| Common Stock | $32.0K | $28.0K | $19.0K | $17.0K | $15.0K | $11.0K | |
| Paid-in Capital | $291M | $281M | $266M | $259M | $255M | $250M | |
| Retained Earnings | $-307M | $-307M | $-301M | $-284M | $-278M | $-269M | |
| AOCI | · | · | · | · | · | $0 | |
| Stockholders' Equity | $-16M | $-26M | $-36M | $-25M | $-23M | $-19M | |
| Liabilities + Equity | $13M | $15M | $5M | $8M | $4M | $4M | |
| Shares Outstanding | 31,734,333 | 27,682,530 | 19,473,588 | 17,120,120 | 14,591,505 | 11,373,246 |
현금 흐름 10
| 지표 | 추세 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|
| D&A | $42.0K | $26.0K | · | · | $1.0K | $2.0K | |
| Stock-based Comp | $81.0K | $68.0K | $67.0K | $12.0K | $43.0K | $104.0K | |
| Operating Cash Flow | $-4M | $-3M | $-4M | $-3M | $-2M | $-2M | |
| CapEx | · | · | · | $0 | · | $0 | |
| Investing Cash Flow | $-249.0K | · | · | $0 | $0 | $0 | |
| Stock Issued | $2M | $4M | $1M | · | $0 | $0 | |
| Financing Cash Flow | $5M | $10M | $1M | $8M | $2M | $2M | |
| Net Change in Cash | $613.0K | $4M | $-3M | $4M | $-203.0K | $-252.0K | |
| Taxes Paid | $0 | $0 | $0 | $0 | $0 | $0 | |
| Free Cash Flow | · | · | · | $-3M | · | · |
수익성 5
| 지표 | 추세 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|
| Operating Margin | · | -1662.8% | · | · | · | · | |
| Net Margin | · | -2433.9% | · | · | · | · | |
| EBITDA Margin | · | -1662.8% | · | · | · | · | |
| ROA | · | -60.5% | -348.1% | -96.9% | · | -18.5% | |
| ROE | · | 26.4% | 65.1% | 27.4% | · | 13.0% |
유동성 및 지급능력 2
| 지표 | 추세 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|
| Current Ratio | · | 0.3 | 0.1 | 0.2 | · | 0.2 | |
| Quick Ratio | · | 0.2 | 0.1 | 0.2 | · | 0.1 |
효율성 2
| 지표 | 추세 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|
| Asset Turnover | · | 0.0 | · | 0.0 | · | · | |
| Receivables Turnover | · | 2.0 | · | · | · | · |
가치 평가 (TTM) 1
| 지표 | 추세 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|---|---|---|
| Net Income TTM | · | $-31M | $-33M | $-22M | · | $-22M |
재무제표 손익계산서, 대차대조표, 현금흐름 — 연간, 지난 5년
손익계산서
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 매출 | $1M | $0 | — | — | — |
| 영업이익률 % | -1324.4% | — | — | — | — |
| 순이익 | $-29M | $-25M | $-30M | $-40M | $-93M |
| 희석 EPS | — | — | — | $-0.60 | $-1.98 |
대차대조표
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 유동비율 | 0.3 | — | — | — | — |
| 당좌 비율 | 0.3 | — | — | — | — |
나의 지표 나만의 관심 목록 — 전체 기본 재무제표에서 선택한 항목
📊
중요한 지표를 선택하세요 — 위 전체 기본 재무제표의 아무 행 옆에 있는 ➕를 클릭하세요.
선택 항목이 저장되어 모든 티커에서 유지됩니다.